ANEB (Anebulo Pharmaceuticals, Inc.) מכפיל EV/Sales

סמלים רשמיים של חברת Anebulo Pharmaceuticals, Inc. (ANEB)

The primary driver for Anebulo Pharmaceuticals (ANEB) is the development of cannabinoid intoxication antidotes for hospitals. The price-to-sales multiple reflects market expectations, with the value holding around 0.00. Stability is ensured by GMP-certified facilities for pilot batches, while high margins are achieved through established express logistics for controlled substances to emergency departments.

Anebulo Pharmaceuticals, Inc. (ANEB) - יחס שווי פעילות להכנסות מ-23.11.2025 עד 07.03.2026

ANEB (Anebulo Pharmaceuticals, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- שער מניה ותחזית מחירי מומחים:
- נתוני יתרות מזומנים ותזרימי מזומנים:
הערכת שווי פונדמנטלית של החברה:Anebulo Pharmaceuticals ANEB
דוגמת מוצר של anebulo.com

This indicator is calculated as the ratio of total enterprise value to sales, allowing for an assessment of the asset's real value without distortions caused by debt load. By analyzing the Enterprise Value to revenue ratio, an investor can determine the premium paid for the potential of Anebulo Pharmaceuticals (ANEB) to create unique antidotes, the demand for which is growing alongside the global legalization of cannabis.